NZ603442A - Treatment of proliferative diseases - Google Patents
Treatment of proliferative diseasesInfo
- Publication number
- NZ603442A NZ603442A NZ603442A NZ60344211A NZ603442A NZ 603442 A NZ603442 A NZ 603442A NZ 603442 A NZ603442 A NZ 603442A NZ 60344211 A NZ60344211 A NZ 60344211A NZ 603442 A NZ603442 A NZ 603442A
- Authority
- NZ
- New Zealand
- Prior art keywords
- proliferative diseases
- vector
- nucleic acid
- host cell
- treatment
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Botany (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Zoology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35812610P | 2010-06-24 | 2010-06-24 | |
| PCT/AU2011/000760 WO2011160174A1 (en) | 2010-06-24 | 2011-06-23 | Treatment of proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ603442A true NZ603442A (en) | 2013-09-27 |
Family
ID=45370753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ603442A NZ603442A (en) | 2010-06-24 | 2011-06-23 | Treatment of proliferative diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120172313A1 (OSRAM) |
| EP (1) | EP2585095A4 (OSRAM) |
| JP (1) | JP2013530965A (OSRAM) |
| KR (1) | KR20140003316A (OSRAM) |
| CN (1) | CN103037888A (OSRAM) |
| AU (1) | AU2011269726B2 (OSRAM) |
| CA (1) | CA2803027A1 (OSRAM) |
| MX (1) | MX2012014711A (OSRAM) |
| NZ (1) | NZ603442A (OSRAM) |
| SG (1) | SG186385A1 (OSRAM) |
| WO (1) | WO2011160174A1 (OSRAM) |
| ZA (1) | ZA201208389B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG192063A1 (en) | 2011-02-07 | 2013-08-30 | Hexima Ltd | Modified plant defensins useful as anti-pathogenic agents |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2755693A4 (en) * | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR |
| WO2013056308A1 (en) * | 2011-10-19 | 2013-04-25 | Balmoral Australia Pty Ltd | Novel forms of plant defensins |
| EP3303376A4 (en) * | 2015-05-29 | 2019-01-23 | Hexima Limited | IN VIVO METHOD |
| CN111751345A (zh) * | 2020-07-08 | 2020-10-09 | 深圳海关动植物检验检疫技术中心 | 一种苜蓿黄萎病菌活性检测方法 |
| KR102371762B1 (ko) * | 2020-12-29 | 2022-03-07 | 중앙대학교 산학협력단 | Brca1 매개 nsd2 유비퀴틴화를 통한 세포 분화 및 세포사멸 조절 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8840401A (en) * | 2000-08-25 | 2002-03-04 | Basf Plant Science Gmbh | Plant polynucleotides encoding novel Na<sup>+</sup>/H<sup>+</sup> antiporters |
| CN1496403B (zh) * | 2001-02-08 | 2010-12-08 | 赫希玛有限公司 | 植物来源分子、其编码遗传序列及其用途 |
| US20070207209A1 (en) * | 2004-08-27 | 2007-09-06 | Murphy Christopher J | Trophic factor combinations for nervous system treatment |
| WO2010015024A1 (en) * | 2008-08-05 | 2010-02-11 | Hexima Limited | Plant anti-pathogen systems |
-
2011
- 2011-06-23 CA CA2803027A patent/CA2803027A1/en not_active Abandoned
- 2011-06-23 WO PCT/AU2011/000760 patent/WO2011160174A1/en not_active Ceased
- 2011-06-23 SG SG2012093050A patent/SG186385A1/en unknown
- 2011-06-23 JP JP2013515634A patent/JP2013530965A/ja active Pending
- 2011-06-23 CN CN2011800312370A patent/CN103037888A/zh active Pending
- 2011-06-23 US US13/166,960 patent/US20120172313A1/en not_active Abandoned
- 2011-06-23 AU AU2011269726A patent/AU2011269726B2/en not_active Ceased
- 2011-06-23 NZ NZ603442A patent/NZ603442A/xx not_active IP Right Cessation
- 2011-06-23 KR KR1020127032033A patent/KR20140003316A/ko not_active Withdrawn
- 2011-06-23 MX MX2012014711A patent/MX2012014711A/es unknown
- 2011-06-23 EP EP11797388.3A patent/EP2585095A4/en not_active Withdrawn
-
2012
- 2012-11-08 ZA ZA2012/08389A patent/ZA201208389B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2585095A4 (en) | 2013-11-13 |
| MX2012014711A (es) | 2013-03-21 |
| CN103037888A (zh) | 2013-04-10 |
| CA2803027A1 (en) | 2011-12-29 |
| JP2013530965A (ja) | 2013-08-01 |
| US20120172313A1 (en) | 2012-07-05 |
| EP2585095A1 (en) | 2013-05-01 |
| KR20140003316A (ko) | 2014-01-09 |
| AU2011269726A1 (en) | 2012-11-29 |
| SG186385A1 (en) | 2013-01-30 |
| ZA201208389B (en) | 2013-06-26 |
| AU2011269726B2 (en) | 2013-11-28 |
| WO2011160174A1 (en) | 2011-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013001613A (es) | Métodos y composiciones para prevenir una afección. | |
| NZ603442A (en) | Treatment of proliferative diseases | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| NZ603901A (en) | Vectors and sequences for the treatment of diseases | |
| WO2017191274A3 (en) | Rna encoding a therapeutic protein | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX342291B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| PH12013502262A1 (en) | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors | |
| JO3776B1 (ar) | التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf | |
| NZ629996A (en) | 2’- substituted carba-nucleoside analogs for antiviral treatment | |
| MX2013003634A (es) | Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales. | |
| MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
| MY191358A (en) | Triazolopyrazines as brd4 inhibitors for use in the treatment of cancer | |
| MX342924B (es) | Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas. | |
| MX2013000821A (es) | Nuevas aminopirazoloquinazolinas. | |
| WO2012024530A3 (en) | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| WO2011038933A3 (en) | Anti-hsv antibody | |
| IN2014DN09963A (OSRAM) | ||
| PH12014501388A1 (en) | A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv | |
| EA202091308A1 (ru) | Модифицированный вакцинный штамм brucella для лечения бруцеллеза | |
| MY186134A (en) | Curcumin-peptide conjugates and formulations thereof | |
| PH12014500250A1 (en) | Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: HEXIMA LIMITED, AU Effective date: 20130926 Owner name: BALMORAL AUSTRALIA PTY LTD, AU Effective date: 20130926 |
|
| S23 | Proceedings under section 23: mention of inventor as such in patent |
Free format text: INVENTOR ANDERSON, MARILYN, ANNE, IVAN, KA HO POON ADDED Effective date: 20130926 Free format text: INVENTOR ANDERSON, MARILYN, KA HO POON, IVAN REMOVED Effective date: 20130926 |
|
| S23 | Proceedings under section 23: mention of inventor as such in patent |
Free format text: INVENTOR BAXTER, AMY ALEXANDRA, LAY, FUNG REMOVED Effective date: 20131003 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUN 2016 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS Effective date: 20150423 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUN 2017 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20160524 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JUN 2018 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD Effective date: 20170515 |
|
| LAPS | Patent lapsed |